Sie suchten nach: endoteljali (Maltesisch - Englisch)

waqt l-istudji kliniċi ma sarx għadd taċ-ċelluli endoteljali.
endothelial cell counts were not conducted during the clinical studies.

toceranib, in-vitro, teżerċita effett antiproliferattiv fuq ċelluli endoteljali.
toceranib exerts an antiproliferative effect on endothelial cells in-vitro.

f’ pazjenti ipergliċemiċi, lisinopril jikontribwixxi sabiex il - funzjoni endoteljali indebolita tiġi restorata.
in hyperglycaemic patients, lisinopril contributes to the restoration of impaired endothelial function.

għaldaqstant, intwera li g- csf jikkaġuna funzjonijiet taċ- ċelluli endoteljali marbuta mal- anġjoġenesi.
accordingly, g-csf has been shown to induce endothelial cell functions related to angiogenesis.

hija tiġi mibdula bil-kumpless trombin/trombomodulin fil-wiċċ endoteljali għal proteina Ċ attivata (apc).
it is converted by thrombin/thrombomodulin-complex on the endothelial surface to activated protein c (apc).

il- kumplessi ta 'l- enzima inibitur- koagulazzjoni jitnehhew mis- sistema retikulo- endoteljali.
the inhibitor-coagulation enzyme complexes are removed by the reticulo-endothelial system.

bħal fil-każ ta’ fatturi ta’ tkabbir ematopojetiċi oħra, g-csf wera proprjetajiet stimolanti in vitro fuq ċelluli endoteljali umani.
as with other haematopoietic growth factors, g-csf has shown in vitro stimulating properties on human endothelial cells.

defibrotide intwera wkoll li jipproteġi ċ-ċelluli endoteljali minn apoptożi medjata bi fludarabine, filwaqt li ma għandux impatt fuq l-effett anti-lewkemiku tiegħu.
defibrotide has also been shown to protect endothelial cells from fludarabine-mediated apoptosis, while not impacting its anti-leukemic effect.

trattament bl-enżima ġie muri li jnaqqas l- akkumulazzjoni ta’ gb3 f’ħafna tipi ta’ ċelloli inklużi ċelloli endoteljali u parenkemali.
treatment with the enzyme has been shown to reduce accumulation of gb3 in many cell types including endothelial and parenchymal cells.

in vitro, cetuximab jinibixxi l-produzzjoni ta’ fatturi anġjoġeniċi minn ċelluli tat-tumur u jimblokka l-migrazzjoni taċ-ċelluli endoteljali.
in vitro cetuximab inhibits the production of angiogenic factors by tumour cells and blocks endothelial cell migration.